Arrhythmias in Patients With Coronavirus Disease 2019 Treated With Hydroxychloroquine and/or Azithromycin
- PMID: 33852488
- DOI: 10.1097/MJT.0000000000001361
Arrhythmias in Patients With Coronavirus Disease 2019 Treated With Hydroxychloroquine and/or Azithromycin
Conflict of interest statement
The authors have no conflicts of interest to declare.
References
-
- Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56:105949.
-
- Yu B, Li C, Chen P, et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. Sci China Life Sci. 2020;63:1515–1521.
-
- Lagier JC, Million M, Gautret P, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: a retrospective analysis. Trav Med Infect Dis. 2020;36:101791.
-
- Nabors C, Sridhar A, Hooda U, et al. Characteristics and outcomes of patients 80 Years and older hospitalized with Coronavirus disease 2019 (COVID-19). Cardiol Rev. 2021;29:39–42.
-
- Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75:2352–2371.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources